{"url_path":"/sec/tnxp/8-k/2026-06-29/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ** **Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1430306/0001493152-26-030408-index.html","accession_number":"0001493152-26-030408","cik":"0001430306","ticker":"TNXP","issuer_name":"Tonix Pharmaceuticals Holding Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1430306/0001493152-26-030408-index.html","primary_entity_key":"0001430306","primary_entity_name":"Tonix Pharmaceuticals Holding Corp."},"word_count":79,"has_tables":true,"body_markdown":"**Item 9.01** **Financial Statements and Exhibits.**\n\n \n\n(d)\n \n\n**Exhibit\nNo.**\n\n \n**Description.**\n\n \n \n\n99.01\n\n \n\n[Press Release of the Company, June 29, 2026](ex99-01.htm)\n\n \n \n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the\nundersigned thereunto duly authorized.\n\n \n\n \n**TONIX\nPHARMACEUTICALS HOLDING CORP.**\n\n \n \n\nDate:\nJune 29, 2026\nBy: \n\n*/s/\nBradley Saenger                    *\n\n \n \nBradley\nSaenger\n\n \n \nChief\nFinancial Officer"}